Candel Therapeutics, Inc. (CADL) News
Track canonical SquawkNews coverage tagged to CADL, Candel Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Candel Therapeutics (CADL) reports Q2 2026 financial results
Candel Therapeutics (CADL) reports its second-quarter 2026 financial results along with recent corporate highlights, according to TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 12:05 PM UTC
L
CADL - Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
CADL - Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
EQUITY | Aug 03, 2026, 12:05 PM UTC
L
CADL - Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston
CADL - Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston
EQUITY | Jul 29, 2026, 12:05 PM UTC
L
Candel Therapeutics Starts Pivotal Phase 3 AURORA Study Of Aglatimagene Besadenovec Plus Valacyclovir In Combination With Continued Pembroli
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL ), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today a
COMMODITIES | Jun 30, 2026, 12:15 PM UTC
L
CADL Appoints CCO
Candel Therapeutics appoints Mark Sims as Chief Commercial Officer
EQUITY | Jun 25, 2026, 12:05 PM UTC